Table 1.
Multivariate analysis of factors predicting prognosis
| Variable | Hazard Ratio (95% CI) | P value |
|---|---|---|
| Progression-free survival in the HGG group | ||
| Chemoradiotherapy | 0.58 (0.41–0.85) | 0.005 |
| LGR5 | 1.64 (1.10–2.43) | 0.012 |
| Peritumoral edema | 1.28 (0.88–1.85) | 0.193 |
| Overall survival in the HGG group | ||
| Chemoradiotherapy | 0.53 (0.32–0.87) | 0.019 |
| LGR5 | 1.65 (1.07–2.53) | 0.024 |
| IDH1 mutation | 0.56 (0.34–0.93) | 0.024 |
| KPS | 0.71 (0.49–1.04) | 0.080 |
| Progression-free survival in the LGG group | ||
| Chemoradiotherapy | 0.18 (0.05–0.62) | 0.007 |
| LGR5 | 2.56 (1.20–5.45) | 0.015 |
| IDH1 mutation | 0.48 (0.23–1.02) | 0.056 |
| Overall survival in the LGG group | ||
| IDH1 mutation | 0.26 (0.09–0.74) | 0.012 |
| LGR5 | 2.08 (0.80–5.42) | 0.136 |
| Chemoradiotherapy | 0.00 (0.00–2.03) | 0.969 |
Abbreviation: HGG high-grade glioma, LGG low-grade glioma, LGR5 leucine-rich repeat-containing G protein-coupled receptor 5, KPS karnofsky performance scale, IDH1 isocitrate dehydrogenase 1, CI confidence interval, NA not available.
Bold and italic value represents P < 0.05 that are considered statistically significant